Rare ovarian tumors: an update on diagnosis and treatment

被引:16
作者
Debuquoy, Charlotte [1 ]
Romeo, Clemence [2 ]
Vanacker, Helene [2 ]
Ray-Coquard, Isabelle [2 ,3 ]
机构
[1] Ctr Leon Berard, Gynecol Surg Dept, Lyon, Rhone Alpes, France
[2] Ctr Leon Berard, Med Oncol, Lyon, Rhone Alpes, France
[3] Univ Claude Bernard, Lab HESPER, Lyon, France
关键词
Ovarian cancer; SMALL-CELL CARCINOMA; GRADE SEROUS OVARIAN; HYPERCALCEMIC TYPE; ADJUVANT CHEMOTHERAPY; RANDOMIZED-TRIAL; CANCER; WOMEN; IMPACT; LYMPHADENECTOMY; BEVACIZUMAB;
D O I
10.1136/ijgc-2020-001235
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Rare ovarian cancers occur frequently. Almost half of ovarian malignancies relate to several different 'rare' histotypes, according to the World Health Organization. The most common tumors are epithelial tumors, including high grade serous carcinomas, the presumed 'frequent ovarian cancers', together with low grade serous, mucinous, endometrioid, clear cell, and carcinosarcomas. Sex cord stromal tumors and germ cell carcinomas define two other groups of different subtypes, and small cell carcinomas are an independent high grade subtype closely related to the family of rhabdoid tumors. All of these cancers are primary ovarian cancers, classified by the International Federation of Gynecology and Obstetrics. However, the tumor subtypes display various epidemiologic, clinical, pathological, prognostic, and therapeutic characteristics. Because of the scarcity of data, current understanding of each subtype is limited and treatment has generally been derived from the more common tumor types. The aim of this article is to review the current literature on rare ovarian malignancies.
引用
收藏
页码:879 / 887
页数:9
相关论文
共 50 条
  • [31] Diagnosis and Treatment of Ovarian Cancer
    Orr, Brian
    Edwards, Robert P.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2018, 32 (06) : 943 - +
  • [32] Update on PARP Inhibitors for the Treatment of Ovarian Cancer
    Liu, Joyce
    Matulonis, Ursula A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2025, 23 (02) : 100 - 110
  • [33] Association between time to diagnosis, time to treatment, and ovarian cancer survival in the United States
    Huepenbecker, Sarah P.
    Sun, Charlotte C.
    Fu, Shuangshuang
    Zhao, Hui
    Primm, Kristin
    Rauh-Hain, Jose Alejandro
    Fleming, Nicole D.
    Giordano, Sharon H.
    Meyer, Larissa A.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 (09) : 1153 - 1163
  • [34] High-Grade Serous Ovarian Cancer during Pregnancy: From Diagnosis to Treatment
    Vivod, Gregor
    Merlo, Sebastjan
    Kovacevic, Nina
    CURRENT ONCOLOGY, 2024, 31 (04) : 1920 - 1935
  • [35] Drug Repositioning for Ovarian Cancer Treatment: An Update
    Cavalluzzi, Maria Maddalena
    Viale, Maurizio
    Rotondo, Natalie Paola
    Ferraro, Valeria
    Lentini, Giovanni
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2024, 24 (08) : 637 - 647
  • [36] Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors
    Horala, Agnieszka
    Swiatly, Agata
    Lorek, Jakub
    Kokot, Zenon J.
    Matysiak, Jan
    Nowak-Markwitz, Ewa
    GINEKOLOGIA POLSKA, 2018, 89 (10) : 568 - 572
  • [37] Contrast-Enhanced Ultrasonography in Differential Diagnosis of Benign and Malignant Ovarian Tumors
    Qiao, Jing-Jing
    Yu, Jing
    Yu, Zhe
    Li, Na
    Song, Chen
    Li, Man
    PLOS ONE, 2015, 10 (03):
  • [38] Diagnosis and treatment of cardiac tumors
    Imai, Toru
    Shimoi, Tatsunori
    Kawai, Akira
    Yonemori, Kan
    MEDICAL ONCOLOGY, 2025, 42 (04)
  • [39] Metastatic penile carcinoma - an update on the current diagnosis and treatment options
    Barski, Dimitri
    Georgas, Evangelos
    Gerullis, Holger
    Ecke, Thorsten
    CENTRAL EUROPEAN JOURNAL OF UROLOGY, 2014, 67 (02) : 126 - 132
  • [40] Neurocysticercosis: an update on diagnosis, treatment, and prevention
    Pineda-Reyes, Roberto
    White, A. Clinton, Jr.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2022, 35 (03) : 246 - 254